toyocamycin has been researched along with cyclosporine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Bodeau, S; Choukroun, G; Descamps, V; François, C; Galmiche, A; Godin, C; Louandre, C; Nyga, R; Sauzay, C | 1 |
2 other study(ies) available for toyocamycin and cyclosporine
| Article | Year |
|---|---|
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Targeting the Unfolded Protein Response as a Potential Therapeutic Strategy in Renal Carcinoma Cells Exposed to Cyclosporine A.
Topics: Carcinoma, Renal Cell; Cell Line, Tumor; Cyclosporine; Endoribonucleases; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Humans; Hypoxia; Immunosuppressive Agents; Kidney Neoplasms; Oxygen; Polymerase Chain Reaction; Protein Serine-Threonine Kinases; Puromycin; RNA Interference; RNA, Small Interfering; Toyocamycin; Unfolded Protein Response; Vascular Endothelial Growth Factor A | 2017 |